abstract: @entity19981 is a dechlorinated derivative of @entity71140 which preclinically synergizes with @entity221 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity5 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity221 treatments. Whole-body @entity221 was delivered using a radiant heat system. Twenty-four @entity1 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity1 with three no responses. Group B (180 mg/m2) consisted of three @entity1 : one @entity706 , partial response; two @entity344 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity1 : two @entity2 , one complete response and one improvement; one @entity320 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity420 of the gastrointestinal tract, two disease stabilizations; 11 @entity1 , no responses; one @entity1 entered at this level was ineligible for study and did not receive @entity19981 . Therapy was well tolerated. Of 16 @entity1 reporting @entity925 , two required a @entity19981 dose reduction; one @entity1 required dose reduction for @entity149 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of @entity19981 with whole body XXXX in @entity5 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancers']

entities_list: @entity149 :: ('MESH:D002493', 'Disease') :: ['central nervous system toxicity']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal adenocarcinomas']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

entities_list: @entity19981 :: ('MESH:C016371', 'Chemical') :: ['lonidamine', 'Lonidamine']

entities_list: @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgias']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']

entities_list: @entity71140 :: ('MESH:C032436', 'Chemical') :: ['indazole-3-carboxylic acid']

answer: @entity221 :: (MESH:D005334,Disease) :: ['hyperthermia']


abstract: @entity19981 is a dechlorinated derivative of @entity71140 which preclinically synergizes with @entity221 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity5 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity221 treatments. Whole-body @entity221 was delivered using a radiant heat system. Twenty-four @entity1 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity1 with three no responses. Group B (180 mg/m2) consisted of three @entity1 : one @entity706 , partial response; two @entity344 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity1 : two @entity2 , one complete response and one improvement; one @entity320 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity420 of the gastrointestinal tract, two disease stabilizations; 11 @entity1 , no responses; one @entity1 entered at this level was ineligible for study and did not receive @entity19981 . Therapy was well tolerated. Of 16 @entity1 reporting @entity925 , two required a @entity19981 dose reduction; one @entity1 required dose reduction for @entity149 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of XXXX with whole body @entity221 in @entity5 .

answer: @entity19981 :: (MESH:C016371,Chemical) :: ['lonidamine']


abstract: @entity19981 is a dechlorinated derivative of @entity71140 which preclinically synergizes with @entity221 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity5 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity221 treatments. Whole-body @entity221 was delivered using a radiant heat system. Twenty-four @entity1 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity1 with three no responses. Group B (180 mg/m2) consisted of three @entity1 : one @entity706 , partial response; two @entity344 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity1 : two @entity2 , one complete response and one improvement; one @entity320 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity420 of the gastrointestinal tract, two disease stabilizations; 11 @entity1 , no responses; one @entity1 entered at this level was ineligible for study and did not receive @entity19981 . Therapy was well tolerated. Of 16 @entity1 reporting @entity925 , two required a @entity19981 dose reduction; one @entity1 required dose reduction for @entity149 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of @entity19981 with whole body @entity221 in XXXX .

answer: @entity5 :: (MESH:D009369,Disease) :: ['advanced cancer']


abstract: Experiments were performed on @entity235 superfused ventricular epicardial tissue slices to determine the effects of 1.0-2.0 mM @entity15264 , an uncoupling agent, on conduction longitudinal and transverse to myocardial fiber orientation. Conduction velocities were measured between proximal and distal pairs of epicardial electrodes oriented transverse and longitudinal to the direction of a conducted wavefront evoked by pacing at a basic cycle length of 2,000 msec from one margin of the tissue before and after the addition of @entity15264 . In a separate group of tissues, the dual bipolar orthogonal electrode was used to sequentially map epicardial activation at 40 to 45 sites in a 1 cm x 2 cm area before and 30 minutes after the introduction of @entity15264 . In a third group of tissues, transmembrane potentials were recorded with standard microelectrode techniques to determine the effects of @entity15264 on action potential characteristics. @entity15264 did not significantly effect action potential amplitude or maximum rate of depolarization. After 1.0 mM @entity15264 , conduction velocity began to decrease in 1-2 minutes and reached a steady state in 15-20 minutes. Conduction velocity in the longitudinal direction decreased from a control value of 0.56 +/- 0.13 to 0.46 +/- 0.10 M/sec (+/- SD) at 30 minutes after @entity15264 (p = 0.005). In the transverse direction, it decreased from 0.24 +/- 0.09 to 0.17 +/- 0.05 M/sec (p = 0.002). The ratio of longitudinal to transverse conduction velocities increased from 2.54 +/- 1.00 to 2.94 +/- 0.82 (p = 0.042). Thus, @entity15264 preferentially slowed conduction in the transverse direction. Because @entity15264 did not greatly influence active membrane properties, we used cable equations to calculate the time course of the change in effective junctional resistivity, which rose from 133.2 omega.cm before @entity15264 to 312.2 omega.cm 30 minutes after @entity15264 administration. We conclude that @entity15264 slows conduction velocity by selectively increasing junctional resistivity. The preferential slowing of conduction in the transverse direction is most likely due to the fact that more junctional resistances are encountered per unit distance in the transverse than in the longitudinal direction.

title: Effects of cellular uncoupling on conduction in anisotropic XXXX ventricular myocardium.

entities_list: @entity15264 :: ('MESH:D019850', 'Chemical') :: ['heptanol', 'Heptanol']

answer: @entity235 :: (9615,Species) :: ['canine']


abstract: The objective of this study was to elucidate the resistive, elastic, and total inspiratory muscle work and mainly the efficiency of the inspiratory muscle work in still standing and in exercising @entity235 . In 180 experiments with nine mongrel @entity235 , respiratory and circulatory functions were recorded at rest and during a 1.5-mph walk on a treadmill belt which was inclined by 9 degrees. Each @entity235 had been trained and surgically prepared before the series of experiments started. An electronic pressure transducer together with a fluid-filled catheter was attached to the ribs at the midthoracic level. Airflow was monitored with a pneumotachygraph attached to a face mask. Aortic flow was monitored with an electromagnetic flow transducer. Catheters in the atria, the ventricles, and the pulmonary and systemic vessels were used to determine hemodynamic parameters and blood gas levels. All recorded and all derived functions were evaluated by a dedicated computer. At rest, resistive inspiratory work (0.98 kg cm) was smaller than elastic work (1.36 kg cm). Elastic work did not change with exercise but resistive work increased to 1.46 kg.cm. The increase of total work from 2.33 kg.cm at rest to 2.79 kg.cm during exercise did not reach significance. Inspiratory power increased with exercise. Estimated diaphragmatic @entity26 consumption increased from 2.23 ml/min at rest to 3.64 ml/min during exercise. It was 1.6 percent of the total @entity26 consumption at rest and 1.7 percent of the total @entity26 consumption during exercise. The estimated efficiency of the work of inspiratory muscles was 15.8 percent at rest and 25.8 percent during exercise. These values did not vary substantially between different animals.

title: Efficiency of work of inspiratory muscles in standing and in exercising XXXX .

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: UNASSIGNED: Sixteen female piglets (58 d of age, 16.8      0.8  kg body weight [BW]) were assigned to two groups (n  =  8) and received until day 100 of age (50.3      1.2  kg BW) ad libitum either a diet with a standard (diet C) or low (diet L) total @entity3151 (P) content (5.38 and 4.23  g/kg, respectively). Diet C was supplemented with mineral P (1.15  g/kg) and did not contain microbial phytase. Diet L did not contain any inorganic P but 750  FTU/kg of microbial phytase. Despite these treatments, both diets were composed with the same ingredients. Body mineralisation of each gilt was assessed by determining the bone mineral content (BMC), area @entity79 ( @entity79 ) by the dual-energy X-ray absorptiometry (DXA) at days 58, 72, 86 and 100 of age. Feeding diet L caused a higher P digestibility (p  =  0.008) measured from days 72 to 86 of age and at 100  days of age a higher BMC and @entity79 (p   <=  0.01). Furthermore, the gilts of group L deposited more minerals in the body than control @entity1707 (by 2.4  g/d, p  =  0.008). It was found that @entity79 and BMC were positively correlated with body lean mass and digestible P intake. The results indicated that, even for very young @entity1707 , the addition of microbial phytase instead of inorganic P increases the amount of digestible P covering the requirements of piglets for proper bone mineralisation. Furthermore, it was proved that the DXA method can be successfully applied to measure body fat and lean mass contents as well as bone mineralisation of growing @entity1707 using the same animals.

title: Bone mineralisation of weaned piglets fed a diet free of inorganic XXXX and supplemented with phytase, as assessed by dual-energy X-ray absorptiometry.

entities_list: @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

answer: @entity3151 :: (MESH:D010758,Chemical) :: ['phosphorus']


abstract: BACKGROUND: Fast and accurate @entity662 risk stratification in the @entity341 ( @entity341 ) is critical. The HEART score predicts the short-term incidence of major adverse @entity299 (MACE) in this population, dividing it in three risk categories. We aimed to describe the population with @entity662 , to characterize the subgroup of @entity1 with @entity1187 ( @entity1187 ) and to assess the prognostic value of Manchester triage system and of HEART score. METHODS: Retrospective observational study including @entity1 admitted to the @entity341 of a tertiary hospital with @entity662 as the presenting symptom. The primary outcome was a composite of all-cause mortality, @entity583 or unscheduled revascularization at 6  weeks. RESULTS: We enrolled 233 @entity1 (age 58        19; 55.4  % males). The most common final diagnosis was non-specific @entity662 (n   =   86, 36.9  %), followed by @entity1187 (n   =   22, 9.4  %). Male gender, smoking and @entity740 were associated with higher risk of @entity1187 . According to Manchester triage system, @entity662 @entity1 stratified with red or orange priority had a higher incidence of @entity1187 (16.5  % vs. 3.8  %, p   =   0.006). The application of HEART score showed that most @entity1 were in low risk category (56.3  %). The six-week incidence of MACE in each category was 2  %, 15.6  % and 76.9  % (p   <   0.001). HEART score accurately predicted the short-term incidence of MACE in @entity662 @entity1 (c-statistic 0.880; 95  % CI, 0.807-0.950, p   <   0.001). CONCLUSIONS: @entity662 @entity1 have very different levels of severity and the discriminatory power of Manchester triage system should be used in the assessment of this population. The HEART score seems to be an effective tool for risk stratification in the @entity341 .

title: @entity662 in the XXXX : risk stratification with Manchester triage system and HEART score.

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['Chest pain', 'chest pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: BACKGROUND: Fast and accurate @entity662 risk stratification in the @entity341 ( @entity341 ) is critical. The HEART score predicts the short-term incidence of major adverse @entity299 (MACE) in this population, dividing it in three risk categories. We aimed to describe the population with @entity662 , to characterize the subgroup of @entity1 with @entity1187 ( @entity1187 ) and to assess the prognostic value of Manchester triage system and of HEART score. METHODS: Retrospective observational study including @entity1 admitted to the @entity341 of a tertiary hospital with @entity662 as the presenting symptom. The primary outcome was a composite of all-cause mortality, @entity583 or unscheduled revascularization at 6  weeks. RESULTS: We enrolled 233 @entity1 (age 58        19; 55.4  % males). The most common final diagnosis was non-specific @entity662 (n   =   86, 36.9  %), followed by @entity1187 (n   =   22, 9.4  %). Male gender, smoking and @entity740 were associated with higher risk of @entity1187 . According to Manchester triage system, @entity662 @entity1 stratified with red or orange priority had a higher incidence of @entity1187 (16.5  % vs. 3.8  %, p   =   0.006). The application of HEART score showed that most @entity1 were in low risk category (56.3  %). The six-week incidence of MACE in each category was 2  %, 15.6  % and 76.9  % (p   <   0.001). HEART score accurately predicted the short-term incidence of MACE in @entity662 @entity1 (c-statistic 0.880; 95  % CI, 0.807-0.950, p   <   0.001). CONCLUSIONS: @entity662 @entity1 have very different levels of severity and the discriminatory power of Manchester triage system should be used in the assessment of this population. The HEART score seems to be an effective tool for risk stratification in the @entity341 .

title: XXXX in the @entity341 : risk stratification with Manchester triage system and HEART score.

answer: @entity662 :: (MESH:D002637,Disease) :: ['Chest pain']


abstract: BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that act as post-transcriptional regulators of gene targets. Accurate quantification of miRNA expression using validated internal controls should aid in the understanding of their role in epigenetic modification of genome function. To date, most studies that have examined miRNA expression levels have used the global mean expression of all expressed genes or the expression of reference mRNAs or nuclear RNAs for normalization. RESULTS: We analyzed the suitability of a number of miRNAs as potential expression normalizers in @entity291 oocytes and early embryos, and porcine oocytes. The stages examined were @entity291 oocytes at the germinal vesicle (GV) and metaphase II stages, @entity291 zygotes, 2, 4 and 8 cell embryos, morulae and blastocysts, as well as porcine cumulus oocyte complexes, GV, metaphase I and II oocytes. qRT-PCR was performed to quantify expression of @entity71141 , miR-103, miR-26a, @entity69539 , @entity71142 , Let-7a and U6 for @entity291 samples and @entity56452 , miR-26a, @entity71141 , miR-103, @entity69540 , @entity71143 and @entity69539 for porcine oocytes. The average starting material for each sample was determined using specific standard curves for each primer set. Subsequently, geNorm and BestKeeper software were used to identify a set of stably expressed miRNAs. Stepwise removal to determine the optimum number of reference miRNAs identified @entity71141 and miR-103 as the most stably expressed in @entity291 samples and miR-26a, @entity69539 and @entity71141 in porcine samples. CONCLUSIONS: The combination of @entity71141 and miR-103 is optimal for normalizing miRNA expression for qPCR experiments on @entity291 oocytes and preimplantation embryos; the preferred combination for porcine oocytes is miR-26a, @entity69539 and @entity71141 .

title: Validating reference microRNAs for normalizing qRT-PCR data in XXXX oocytes and preimplantation embryos.

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: A 50-year-old @entity1 presented with @entity491 , @entity417 , and @entity882 in June 2013. She was diagnosed with de novo @entity3052 with the t(16;21)(q24;q22) translocation. She received an allogeneic hematopoietic stem cell transplant from an @entity1533 locus-mismatched unrelated donor in June 2014. The myeloablative preparative regimen consisted of @entity786 at 60 mg/kg for 2 days and total body irradiation at 12 Gy. On Day 55, she was treated with @entity617 at 20 mg/day for acute GVHD (Grade III; Skin Stage 2, Gut Stage 2, Liver Stage 0) and gradually improved. She had @entity221 , @entity925 in the upper limbs, and asymptomatic @entity7129 on Day 145. Laboratory tests showed elevated CK, CKMB, aldolase, and troponin I. Electromyographic examination revealed @entity121 compatible with the diagnosis of @entity5442 . Electrocardiography showed @entity591 and anteroseptal ST elevation, and echocardiography showed @entity2845 of the left interventricular septal wall without evidence of @entity281 or @entity1778 relapse. She was immediately treated with 40 mg/day @entity617 after the diagnosis of @entity6558 and @entity296 , associated with chronic GVHD. The @entity6558 and @entity296 improved promptly after the administration of @entity617 and the @entity1 remains in remission with a current maintenance program of @entity617 at 5 mg/day.

title: Chronic GVHD complicated with @entity6558 and XXXX after myeloablative hematopoietic stem cell transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathic abnormalities']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

entities_list: @entity2845 :: ('MESH:D018476', 'Disease') :: ['hypokinesia']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity6558 :: ('MESH:D017285', 'Disease') :: ['polymyositis']

entities_list: @entity7129 :: ('MESH:D013616', 'Disease') :: ['sinus tachycardia']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity296 :: (MESH:D009202,Disease) :: ['cardiomyopathy']


abstract: A 50-year-old @entity1 presented with @entity491 , @entity417 , and @entity882 in June 2013. She was diagnosed with de novo @entity3052 with the t(16;21)(q24;q22) translocation. She received an allogeneic hematopoietic stem cell transplant from an @entity1533 locus-mismatched unrelated donor in June 2014. The myeloablative preparative regimen consisted of @entity786 at 60 mg/kg for 2 days and total body irradiation at 12 Gy. On Day 55, she was treated with @entity617 at 20 mg/day for acute GVHD (Grade III; Skin Stage 2, Gut Stage 2, Liver Stage 0) and gradually improved. She had @entity221 , @entity925 in the upper limbs, and asymptomatic @entity7129 on Day 145. Laboratory tests showed elevated CK, CKMB, aldolase, and troponin I. Electromyographic examination revealed @entity121 compatible with the diagnosis of @entity5442 . Electrocardiography showed @entity591 and anteroseptal ST elevation, and echocardiography showed @entity2845 of the left interventricular septal wall without evidence of @entity281 or @entity1778 relapse. She was immediately treated with 40 mg/day @entity617 after the diagnosis of @entity6558 and @entity296 , associated with chronic GVHD. The @entity6558 and @entity296 improved promptly after the administration of @entity617 and the @entity1 remains in remission with a current maintenance program of @entity617 at 5 mg/day.

title: Chronic GVHD complicated with XXXX and @entity296 after myeloablative hematopoietic stem cell transplantation.

answer: @entity6558 :: (MESH:D017285,Disease) :: ['polymyositis']


abstract: OBJECTIVES: Matrix metalloproteinases (MMPs) has been implicated in the pathogenesis of infective, @entity5 and @entity792 . In this study, we investigated the serum level of MMPs and its clinical importance in @entity1 @entity3377 . @entity1 AND METHODS: This study included 60 @entity3377 @entity1 treated at the Clinic for Infectious Diseases, Clinical Centre, University of Sarajevo. Matrix metalloproteinases serum levels were quantified by ELISA. RESULTS: The investigation involved three groups: 30 @entity1 with complications, 30 @entity1 without complications of @entity3377 and 30 healthy control examinees. The complications of @entity1 @entity3377 varied but osteoarticular involvement dominated (n=21/30; 70%). Matrix metalloproteinases serum levels in the @entity1 with complications were highest. The serum level of @entity3334 in @entity1 with complications was the highest at 9.45; in @entity1 without complications it was 3.78 and in the control examinees it was lowest at 3.62 (p=0.001). The serum level of @entity1495 in @entity1 with complications was the highest at 105.66; in @entity1 without complications 64.67, and in the control examinees it was lowest at 37.32 (p=0.001). The serum level of MMP-13 in @entity1 with complications was highest at 138.86; in @entity1 without complications at 64.85; and in the control examinees it was the lowest at 29.55 (p=0.001). Pearson's coefficient showed a statistically significant positive correlation between levels of tested matrix metalloproteinases and development complications in @entity1 @entity3377 (p=0.001). CONCLUSION: This study showed the diagnostic value and importance of detection of matrix metalloproteinases in @entity1 @entity3377 . MMPs are a useful serum biomarker for assessment of disease activity.

title: Osteoarticular complications of XXXX : The diagnostic value and importance of detection matrix metalloproteinases.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'PATIENTS']

entities_list: @entity3377 :: ('MESH:D002006', 'Disease') :: ['brucellosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']

answer: @entity3377 :: (MESH:D002006,Disease) :: ['brucellosis']


abstract: BACKGROUND: Because large, prospective, population-based data sets describing maternal outcomes are typically not available in low- and middle-income countries, it is difficult to monitor maternal mortality rates over time and to identify factors associated with maternal mortality. Early identification of risk factors is essential to develop comprehensive intervention strategies preventing @entity14422 . Our objective was to describe maternal mortality rates in a large, multi-country dataset and to determine maternal, pregnancy-related, delivery and postpartum characteristics that are associated with maternal mortality. METHODS: We collected data describing all pregnancies from 2010 to 2013 among @entity1 enrolled in the multi-national Global Network for @entity1 's and @entity1 's Health Research Maternal and Neonatal Health Registry (MNHR). We reported the proportion of mothers who died per pregnancy and the maternal mortality ratio (MMR). Generalized linear models were used to evaluate the relationship of potential medical and social factors and maternal mortality and to develop point and interval estimates of relative risk associated with these factors. Generalized estimating equations were used to account for the correlation of outcomes within cluster to develop appropriate confidence intervals. RESULTS: We recorded 277,736 pregnancies and 402 maternal deaths for an MMR of 153/100,000 live births. We observed an improvement in the total MMR from 166 in 2010 to 126 in 2013. The MMR in Latin American sites (91) was lower than the MMR in Asian (178) and African sites (125). When adjusted for study site and the other variables, no formal education (RR 3.2 [1.5, 6.9]), primary education only (RR 3.4 [1.6, 7.5]), secondary education only (RR 2.5 [1.1, 5.7]), lack of antenatal care (RR 1.8 [1.2, 2.5]), caesarean section delivery (RR 1.9 [1.3, 2.8]), @entity548 (RR 3.3 [2.2, 5.1]), and @entity101 (RR 7.4 [5.2, 10.4]) were associated with higher risks of @entity204 . CONCLUSIONS: The MNHR identified preventable causes of maternal mortality in diverse settings in low- and middle-income countries. The MNHR can be used to monitor public health strategies and determine their association with reducing maternal mortality. TRIAL REGISTRATION: clinicaltrials.gov NCT01073475.

title: Risk factors for XXXX and trends in maternal mortality in low- and middle-income countries: a prospective longitudinal cohort analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Children', 'Women']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive disorders']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity14422 :: ('MESH:D011248', 'Disease') :: ['pregnancy-related complications']

answer: @entity204 :: (MESH:D003643,Disease) :: ['maternal death']


abstract: PURPOSE: There are very few reported cases of @entity2054 following spinal surgery via a posterior approach. An association between @entity2054 and muscle over-activity via nerve stimulation during evoked potential monitoring was first suggested in 2003. No further reports have suggested this link. We present a multicentre retrospective review of a series of five @entity1 who developed @entity2054 following spinal surgery via a posterior approach, whilst un-paralysed and with combined sensory (SSEP)/motor evoked potential (MEP) monitoring with an aim of highlighting this possible causative factor. METHODS: All data were collected contemporaneously and retrospective analysis was performed. We then arranged for a multidisciplinary review of the cases including surgeons, anaesthetists, radiologists, neurophysiologists and theatre and ward nursing staff. Finally, the literature was reviewed. RESULTS: All @entity1 were operated on by three different surgeons, on different operating tables/mattresses in the prone position. The common factors were un-paralysed @entity1 having motor/sensory monitoring, mechanical @entity291 pumps and total intravenous anaesthesia. Three @entity1 underwent surgical decompression of their compartments and two were treated expectantly. Three @entity1 had confirmed intra-compartmental changes on MRI consistent with @entity2054 and one had intra-compartmental pressure monitoring which confirmed the diagnosis. CONCLUSIONS: Previous cases in the literature have related to mal-positioning on the Jackson table or use of the knee-chest position for surgery. This was not the case for our @entity1 ; therefore, we suspect an association between overactive muscle stimulation and @entity121 . Further experimental studies investigating this link are required.

title: A multicentre retrospective review of XXXX of the leg following spinal surgery with motor evoked potential monitoring: a cause for concern?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2054 :: ('MESH:D003161', 'Disease') :: ['compartment syndrome', 'compartment syndrome of the leg']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle necrosis']

answer: @entity121 :: (MESH:D009135,Disease) :: ['muscle necrosis']


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity3988 (DT) and @entity1855 (VP) on muscle contraction. @entity95 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity141 -activated @entity2701 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity141 -activated @entity2701 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity141 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity5834 -induced @entity2701 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity141 release from the SR or enhanced @entity5834 -induced @entity2701 transients with the exception that in PM, DT attenuated @entity5834 -induced @entity2701 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity460 release from the SR and increase @entity141 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity2701 , and inducing @entity1159 .

title: Intracellular mechanisms of XXXX and @entity3988 action on striated muscle of the @entity95 .

entities_list: @entity1855 :: ('MESH:D014700', 'Chemical') :: ['verapamil']

entities_list: @entity5834 :: ('MESH:D002110', 'Chemical') :: ['caffeine']

entities_list: @entity3988 :: ('MESH:D004110', 'Chemical') :: ['diltiazem']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1159 :: ('MESH:D003286', 'Disease') :: ['contracture in skeletal muscle']

answer: @entity1855 :: (MESH:D014700,Chemical) :: ['verapamil']


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity3988 (DT) and @entity1855 (VP) on muscle contraction. @entity95 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity141 -activated @entity2701 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity141 -activated @entity2701 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity141 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity5834 -induced @entity2701 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity141 release from the SR or enhanced @entity5834 -induced @entity2701 transients with the exception that in PM, DT attenuated @entity5834 -induced @entity2701 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity460 release from the SR and increase @entity141 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity2701 , and inducing @entity1159 .

title: Intracellular mechanisms of @entity1855 and XXXX action on striated muscle of the @entity95 .

answer: @entity3988 :: (MESH:D004110,Chemical) :: ['diltiazem']


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity3988 (DT) and @entity1855 (VP) on muscle contraction. @entity95 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity141 -activated @entity2701 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity141 -activated @entity2701 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity141 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity5834 -induced @entity2701 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity141 release from the SR or enhanced @entity5834 -induced @entity2701 transients with the exception that in PM, DT attenuated @entity5834 -induced @entity2701 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity460 release from the SR and increase @entity141 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity2701 , and inducing @entity1159 .

title: Intracellular mechanisms of @entity1855 and @entity3988 action on striated muscle of the XXXX .

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: UNASSIGNED: We used samples from @entity309 ( @entity309 ) @entity1 to examine whether Anti-citrullinated protein antibodies (ACPAs) alter macrophage subset distribution and promote @entity309 development. Macrophage subset distributions and @entity20630 ( @entity20630 ) and @entity22367 expressions were analyzed. ACPAs were purified by affinity column. After @entity309 and @entity571 ( @entity571 ) @entity1 ' macrophages were cocultured with ACPAs, macrophage subsets and @entity20630 and @entity22367 expressions were measured. Small interfering RNAs (siRNAs) were transfected into @entity7134 -activated cells to suppress @entity20630 or @entity22367 . Fluorescence-activated cell sorting (FACS), Western blot, and immunohistochemistry were performed. Macrophage subset disequilibrium occurred in @entity309 @entity1 synovial fluids. @entity20630 and @entity22367 were all expressed in the synovial fluid and synovium. ACPAs (40  IU/ml) could induce macrophages to polarize to M1 subsets, and the percentage of increased M1/M2 ratio of @entity309 @entity1 was higher than that of the @entity571 @entity1 . ACPAs also induce @entity20630 and @entity22367 protein expressions. @entity22367 siRNA transfection impaired @entity7134 activity significantly. We demonstrated that macrophage subset disequilibrium occurred in @entity309 @entity1 . ACPAs induced @entity22367 activity and led to M1 macrophage polarization.

title: Anti-Citrullinated Protein Antibodies Induce Macrophage Subset Disequilibrium in XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['OA', 'osteoarthritis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

entities_list: @entity20630 :: ('3662', 'Gene') :: ['interferon regulatory factor 4', 'IRF4']

answer: @entity309 :: (MESH:D001172,Disease) :: ['RA']


abstract: UNASSIGNED: We used samples from @entity309 ( @entity309 ) @entity1 to examine whether Anti-citrullinated protein antibodies (ACPAs) alter macrophage subset distribution and promote @entity309 development. Macrophage subset distributions and @entity20630 ( @entity20630 ) and @entity22367 expressions were analyzed. ACPAs were purified by affinity column. After @entity309 and @entity571 ( @entity571 ) @entity1 ' macrophages were cocultured with ACPAs, macrophage subsets and @entity20630 and @entity22367 expressions were measured. Small interfering RNAs (siRNAs) were transfected into @entity7134 -activated cells to suppress @entity20630 or @entity22367 . Fluorescence-activated cell sorting (FACS), Western blot, and immunohistochemistry were performed. Macrophage subset disequilibrium occurred in @entity309 @entity1 synovial fluids. @entity20630 and @entity22367 were all expressed in the synovial fluid and synovium. ACPAs (40  IU/ml) could induce macrophages to polarize to M1 subsets, and the percentage of increased M1/M2 ratio of @entity309 @entity1 was higher than that of the @entity571 @entity1 . ACPAs also induce @entity20630 and @entity22367 protein expressions. @entity22367 siRNA transfection impaired @entity7134 activity significantly. We demonstrated that macrophage subset disequilibrium occurred in @entity309 @entity1 . ACPAs induced @entity22367 activity and led to M1 macrophage polarization.

title: Anti-Citrullinated Protein Antibodies Induce Macrophage Subset Disequilibrium in @entity309 XXXX .

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: UNASSIGNED: @entity101 has been the second most important determinant of disease burden in Iran since the 1990s. Despite well-recognized evidence on the association of high blood pressure and mortality in other countries, this relationship has not been fully investigated in the demographic setting of Iran. The current study is the first large-scale longitudinal study of this association in Iran. Briefly, 50   045 subjects between 40 and 75 years of age have been recruited and followed. Blood pressure measurements were carried out at baseline. Causes of @entity204 were reported and verified by verbal autopsy throughout the follow-up period. The outcomes of interest were all-cause @entity204 and @entity204 due to @entity741 ( @entity741 ) or @entity64 . Cox proportional hazards regression models were used to estimate hazard ratios (HRs). A total of 46 674 subjects free from @entity65 at baseline were analyzed. Absolute mortality rates increased along with increasing systolic or diastolic blood pressure above 120 and 80   mm   Hg, respectively. Adjusted HRs (95% confidence intervals) for each 20   mm   Hg increase in systolic blood pressure in all age groups were 1.18 (1.13-1.23) for all-cause mortality, 1.21 (1.13-1.31) for @entity204 due to @entity741 and 1.50 (1.39-1.63) for @entity204 due to @entity64 . Unadjusted and adjusted HRs were higher in younger subjects and decreased with increasing age of the @entity1 . @entity101 is a serious threat to the health of Iranians. The entire health-care system of Iran should be involved in a comprehensive action plan for controlling blood pressure.Journal of @entity1 @entity101 advance online publication, 11 June 2015; doi:10.1038/jhh.2015.57.

title: XXXX and mortality in the Golestan Cohort Study: A prospective study of 50   000 adults in Iran.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Human']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['High blood pressure', 'Hypertension']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['IHD', 'ischemic heart disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity101 :: (MESH:D006973,Disease) :: ['Hypertension']


abstract: OBJECTIVE: To compare the video-assisted thoracoscopic surgery (VATS) with the open thoracotomy access to @entity358 by the clinical outcomes and long-term survival in @entity2 . METHODS: Non-randomized comparative intention-to-treat study of prospective institutional registry data and survival data of 100 consecutive @entity1 undergoing segmentectomy. RESULTS: Within one decade (2002-12), 100 @entity1 with proven or highly suspected @entity2 underwent 100 anatomical sub-lobar pulmonary resections (52 typical and 20 atypical segmentectomies, 28 split-lobe procedures). Fifty-six @entity1 were operated by VATS and 44 by thoracotomy access. Comparison of demographic, medical, oncological and surgical baseline data did not provide evidence for differences between the VATS and thoracotomy groups. The surgery time for the VATS group was 225    62 min and 195    57 min for the thoracotomy group (P = 0.014). Postoperative hospitalization was 9 days for the VATS group and 12 days for the thoracotomy group (P = 0.034). Postoperative morbidity was 35.7% for the VATS group and 50% for the thoracotomy group (P = 0.161). Both groups had no 30-day mortality. Conversion to thoracotomy occurred in 30.4% of the VATS group. Conversion was more frequent in @entity1 with male gender, critical and prohibitive lung function, @entity5 with diameters exceeding 3 cm and atypical segmentectomies. The fractions of the pathological Union international contre le @entity5 (UICC) stages I, II and III were 74.4, 11.6 and 14% in the VATS group, and 70, 20 and 10% in the thoracotomy group (P = 0.445), respectively. Five-year overall survival was 86% in the VATS group and 69.9% in the thoracotomy group (P = 0.047), and 5-year recurrence-free survival was 58.5 and 48.6% (P = 0.480), respectively. CONCLUSIONS: Compared with thoracotomy access, the VATS approach to segmentectomy was associated with less postoperative morbidity and a 25% decrease in median hospital stay, despite a conversion rate of 30% due to the inclusion of atypical segmentectomies, higher @entity5 stages and @entity1 with critical function for single lung ventilation. Five-year survival estimates suggested a small but significant overall survival benefit and a 10% difference of recurrence-free survival in favour of VATS. Although not fully conclusive, long-term results indicate that the thoracoscopic access to segmentectomy is probably not inferior to the thoracotomy approach. Confirmation by a larger number of risk-adjusted outcome data is required.

title: Comparative intention-to-treat analysis of the video-assisted thoracoscopic surgery approach to XXXX   .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary segmentectomy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'tumour']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung carcinoma']

answer: @entity2 :: (MESH:D008175,Disease) :: ['pulmonary segmentectomy for lung carcinoma']


abstract: UNASSIGNED: Botulinum toxin is a widely used treatment with satisfactory results, and it is relatively safe in the doses used for cosmetic procedures. The authors report a case of @entity56 to Chinese botulinum toxin serotype A (CBTX-A). Although this is a rare adverse event, it is nonetheless clinically relevant to healthcare professionals. A 44-year-old @entity1 presented to the authors' hospital complaining of dynamic wrinkles. CBTX-A was used to treat her. Minutes after application, she developed urticarial plaques proximal to the injection site. The @entity1 had an @entity56 , as documented by a positive skin test, which was controlled by the administration of antihistamines and systemic @entity288 . This report is intended to guide healthcare professionals faced with this type of adverse event regarding how to proceed without hindering the delivery and effectiveness of the treatment. When performed by a qualified health professional, this treatment brings excellent results in the vast majority of cases. LEVEL OF EVIDENCE: 5 Risk.

title: Report of XXXX After Application of Botulinum Toxin.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic reaction']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity56 :: (MESH:D004342,Disease) :: ['Allergic Reaction']


abstract: The persistence of collateral circulation was evaluated one year after the correction of experimental @entity1498 ( @entity9931 ) by assessing renal perfusion with the Xenon 133-washout method and measuring distal aortic blood pressure during cross-clamping of the thoracic aorta. @entity9931 was created in 7 puppies at 2 months of age and was corrected after a follow-up with a venous patch when the @entity235 were 9 months old. Two of the @entity235 were lost during the corrective operation due to anaesthetic complications. Four sham-operated @entity235 served as controls. One year after correction of @entity9931 , four of the @entity235 had a pressure gradient of less than 5 mmHg at the site of @entity9931 and one a pressure gradient of 15 mmHg. In renal perfusion measurements a mean decrease of 49% and 96% was found in the study and control groups, respectively. Blood pressures in the distal aorta decreased 47% and 83%, respectively. Two @entity235 in the study group had a distal blood pressure under 50 mmHg and their renal perfusion decreased markedly. Collateral circulation decreased with time after a good anatomic correction of @entity9931 , so that one year after correction of experimental @entity9931 about one half of the initial collateral capacity remained. This suggests that in most reoperations performed at least one year after the primary corrections, temporal shunting or a left side bypass is necessary to ensure sufficient circulation in the distal organs.

title: Persistence of collateral circulation after correction of XXXX .

entities_list: @entity1498 :: ('MESH:D001017', 'Disease') :: ['aortic coarctation']

answer: @entity1498 :: (MESH:D001017,Disease) :: ['aortic coarctation']


abstract: BACKGROUND: @entity472 ( @entity472 ) shares several similarities with @entity731 . Recent reports showed that B cells are implicated in @entity731 progression through macrophage-B cells bidirectional interaction. We aimed to study the in loco presence of B cells within aortic valves and to determine its modulators. METHODS: Thirty-seven @entity1 with severe @entity472 were studied. Immunohistochemistry was performed on valve leaflets using antibodies against @entity2225 , B cell-activating factor of the @entity5 necrosis factor family receptor ( @entity25869 ) and @entity469 . Plasma inflammatory markers were also determined. RESULTS: The B cells were detected within aortic leaflets from 5 to 31/mm(2) (17.9  11.6/mm(2)). Double-staining showed that 27  13.5% of B cells express @entity25869 . There were positive correlations between the number of B cells and macrophages (r=0.45, p=0.018), and between macrophages and B cell-associated @entity25869 expression (r=0.66, p=0.002). The number of B cells was associated with the valve @entity730 (r=0.41, p=0.039), and with the maximum transvalvular gradient (r=0.63, p=0.02). The @entity25869 expression was positively correlated with maximum transvalvular gradient (r=0.39, p=0.031) and negatively with aortic valve area (r=-0.41, p=0.048). There were no correlations between the number of B cells and plasma markers. CONCLUSIONS: It might be hypothesized that, like in @entity731 , increasing number of B cells within aortic valves may accelerate @entity32 and thus potentiate the progression of @entity472 .

title: Presence of B cells within aortic valves in @entity1 with XXXX : Relation to severity of the disease.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['AS', 'Aortic stenosis']

answer: @entity472 :: (MESH:D001024,Disease) :: ['aortic stenosis']


abstract: BACKGROUND: @entity472 ( @entity472 ) shares several similarities with @entity731 . Recent reports showed that B cells are implicated in @entity731 progression through macrophage-B cells bidirectional interaction. We aimed to study the in loco presence of B cells within aortic valves and to determine its modulators. METHODS: Thirty-seven @entity1 with severe @entity472 were studied. Immunohistochemistry was performed on valve leaflets using antibodies against @entity2225 , B cell-activating factor of the @entity5 necrosis factor family receptor ( @entity25869 ) and @entity469 . Plasma inflammatory markers were also determined. RESULTS: The B cells were detected within aortic leaflets from 5 to 31/mm(2) (17.9  11.6/mm(2)). Double-staining showed that 27  13.5% of B cells express @entity25869 . There were positive correlations between the number of B cells and macrophages (r=0.45, p=0.018), and between macrophages and B cell-associated @entity25869 expression (r=0.66, p=0.002). The number of B cells was associated with the valve @entity730 (r=0.41, p=0.039), and with the maximum transvalvular gradient (r=0.63, p=0.02). The @entity25869 expression was positively correlated with maximum transvalvular gradient (r=0.39, p=0.031) and negatively with aortic valve area (r=-0.41, p=0.048). There were no correlations between the number of B cells and plasma markers. CONCLUSIONS: It might be hypothesized that, like in @entity731 , increasing number of B cells within aortic valves may accelerate @entity32 and thus potentiate the progression of @entity472 .

title: Presence of B cells within aortic valves in XXXX with @entity472 : Relation to severity of the disease.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: It is important to identify @entity65 in @entity1 at high risk. To include genetics into routine cardiological @entity1 has therefore been discussed recently. We wanted to evaluate the association between high-molecular weight @entity1254 and cardiovascular risk, and secondly in the same population evaluate if specific genotype differences regarding risk could be observed, and thirdly if gender differences could be seen. METHOD: Four hundred seventy-six elderly @entity1 recruited from a rural community were included. All @entity1 underwent a clinical examination, echocardiography, and blood sampling and the single nucleotide polymorphism (SNP) ( @entity29124 ) of @entity1254 was analysed. Follow-up time was 6.7 years. RESULTS: Those with high serum concentration of @entity1254 had a more 2 fold increased cardiovascular risk, and it might be that females exhibits even higher risk where a more than 5 fold increased risk could be seen. The result could be demonstrated even in a multivariate model adjusting for well-known clinical risk factors. However, as the sample size was small the gender differences should be interpreted with caution. In the genotype evaluation the C/C carriers of the female group had a more than 9-fold increased risk of @entity65 , however the confidence interval was wide. Such genotype difference could not be found in the male group. CONCLUSION: High level of @entity1254 was associated with increased cardiovascular risk. Also a gender difference in the genotype evaluation could be seen where the C/C carriers obtained higher risk in the female group but not in the male group. Thus, in order to identify @entity1 at risk early, genetic analyses may add to the armamentarium used in the clinical routine. However, information should be regarded as hypothesis generating as the sample size was small and should stimulate further research in individualized cardiovascular prevention and treatment.

title: Gender difference in @entity1254 associated with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality', 'cardiovascular diseases']

answer: @entity65 :: (MESH:D002318,Disease) :: ['cardiovascular mortality']


abstract: BACKGROUND: It is important to identify @entity65 in @entity1 at high risk. To include genetics into routine cardiological @entity1 has therefore been discussed recently. We wanted to evaluate the association between high-molecular weight @entity1254 and cardiovascular risk, and secondly in the same population evaluate if specific genotype differences regarding risk could be observed, and thirdly if gender differences could be seen. METHOD: Four hundred seventy-six elderly @entity1 recruited from a rural community were included. All @entity1 underwent a clinical examination, echocardiography, and blood sampling and the single nucleotide polymorphism (SNP) ( @entity29124 ) of @entity1254 was analysed. Follow-up time was 6.7 years. RESULTS: Those with high serum concentration of @entity1254 had a more 2 fold increased cardiovascular risk, and it might be that females exhibits even higher risk where a more than 5 fold increased risk could be seen. The result could be demonstrated even in a multivariate model adjusting for well-known clinical risk factors. However, as the sample size was small the gender differences should be interpreted with caution. In the genotype evaluation the C/C carriers of the female group had a more than 9-fold increased risk of @entity65 , however the confidence interval was wide. Such genotype difference could not be found in the male group. CONCLUSION: High level of @entity1254 was associated with increased cardiovascular risk. Also a gender difference in the genotype evaluation could be seen where the C/C carriers obtained higher risk in the female group but not in the male group. Thus, in order to identify @entity1 at risk early, genetic analyses may add to the armamentarium used in the clinical routine. However, information should be regarded as hypothesis generating as the sample size was small and should stimulate further research in individualized cardiovascular prevention and treatment.

title: Gender difference in XXXX associated with @entity65 .

answer: @entity1254 :: (9370,Gene) :: ['adiponectin']


abstract: AIMS: To elucidate if topically applied @entity2993 safely decreases corneal @entity941 staining in dry eyes associated with @entity14985 . METHODS: Ten @entity936 and @entity14985 (DEB) @entity1 were enroled in a prospective pilot study. All @entity1 were treated with topical @entity2993 (50  M) 8 times a day for 4 weeks and allowed to continue with their existing @entity936 treatment. The @entity1 were examined weekly for 4 weeks. The primary outcome measure was corneal @entity941 staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, @entity14985 score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. RESULTS: An improvement in corneal @entity941 staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 @entity1 (p < 0.01). Topical @entity2993 significantly improved the tear film BUT (p < 0.01), @entity14985 score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. CONCLUSION: Topical @entity2993 is a potential therapy for DEB @entity1 . Larger comparative clinical studies are required to establish the efficacy and safety of topical @entity2993 .    2015 S. Karger AG, Basel.

title: Efficacy and Safety of Topical @entity2993 for the Treatment of Dry Eye Associated with XXXX : A Pilot Study.

entities_list: @entity14985 :: ('MESH:D001762', 'Disease') :: ['blepharitis']

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

answer: @entity14985 :: (MESH:D001762,Disease) :: ['Blepharitis']


abstract: AIMS: To elucidate if topically applied @entity2993 safely decreases corneal @entity941 staining in dry eyes associated with @entity14985 . METHODS: Ten @entity936 and @entity14985 (DEB) @entity1 were enroled in a prospective pilot study. All @entity1 were treated with topical @entity2993 (50  M) 8 times a day for 4 weeks and allowed to continue with their existing @entity936 treatment. The @entity1 were examined weekly for 4 weeks. The primary outcome measure was corneal @entity941 staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, @entity14985 score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. RESULTS: An improvement in corneal @entity941 staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 @entity1 (p < 0.01). Topical @entity2993 significantly improved the tear film BUT (p < 0.01), @entity14985 score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. CONCLUSION: Topical @entity2993 is a potential therapy for DEB @entity1 . Larger comparative clinical studies are required to establish the efficacy and safety of topical @entity2993 .    2015 S. Karger AG, Basel.

title: Efficacy and Safety of Topical XXXX for the Treatment of Dry Eye Associated with @entity14985 : A Pilot Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity2993 :: (MESH:C065179,Chemical) :: ['Atorvastatin']


abstract: PURPOSE: By integrating intraoperative near infrared fluorescence imaging into a robotic system, surgeons can identify the vascular anatomy in real-time with the technical advantages of robotics that is useful for meticulous lymphovascular dissection. Herein, we report our initial experience of robotic low ligation of the inferior mesenteric artery (IMA) with real-time identification of the vascular system for @entity5 using the Firefly technique. MATERIALS AND METHODS: The study group included 11 @entity1 who underwent a robotic total mesorectal excision with preservation of the left colic artery for @entity5 using the Firefly technique between July 2013 and December 2013. RESULTS: The procedures included five low anterior resections and six ultra-low anterior resections with loop ileostomy. The median total operation time was 327 min (226-490). The low ligation time was 10 min (6-20), and the time interval between @entity3194 injection and division of the sigmoid artery was 5 min (2-8). The estimated @entity190 was 200 mL (100-500). The median time to soft diet was 4 days (4-5), and the median length of stay was 7 days (5-9). Three @entity1 developed @entity260 ; one @entity1 developed @entity850 , one developed ileus, and one developed non-complicated intraabdominal fluid collection. The median total number of lymph nodes harvested was 17 (9-29). CONCLUSION: Robotic low ligation of the IMA with real-time identification of the vascular system for @entity5 using the Firefly technique is safe and feasible. This technique can allow for precise lymph node dissection along the IMA and facilitate the identification of the left colic branch of the IMA.

title: Robotic Low Ligation of the Inferior Mesenteric Artery for XXXX Using the Firefly Technique.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity3194 :: ('MESH:D007208', 'Chemical') :: ['indocyanine green']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['anal stricture']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Rectal Cancer']


abstract: Numerous @entity5 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity3167 ( @entity35419 ). CA 19-9 is a @entity1735 antigen found on the membrane surface of pancreatic, gastric, and @entity694 . A prospective study involving 25 @entity1 (15 males, 10 females) with @entity1358 ( @entity1358 ) was undertaken to examine the clinical value of these two markers. @entity1 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity1 . Twenty three of the 25 had known disease present when tested. Eleven @entity1 with no known @entity5 were used as an age-matched control group. Sixteen of the 23 @entity1 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity1 (82%) had normal LASA values. Three of 7 @entity1 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity1 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity5 stage. CA 19-9 values obtained in 15 of 25 @entity1 with @entity1358 were within normal range.

title: Significance of lipid-associated @entity3167 and CA 19-9 as @entity5 markers for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['sialic acid']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasms']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['RCC', 'renal cell carcinoma']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic cancers']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']


abstract: Numerous @entity5 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity3167 ( @entity35419 ). CA 19-9 is a @entity1735 antigen found on the membrane surface of pancreatic, gastric, and @entity694 . A prospective study involving 25 @entity1 (15 males, 10 females) with @entity1358 ( @entity1358 ) was undertaken to examine the clinical value of these two markers. @entity1 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity1 . Twenty three of the 25 had known disease present when tested. Eleven @entity1 with no known @entity5 were used as an age-matched control group. Sixteen of the 23 @entity1 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity1 (82%) had normal LASA values. Three of 7 @entity1 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity1 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity5 stage. CA 19-9 values obtained in 15 of 25 @entity1 with @entity1358 were within normal range.

title: Significance of lipid-associated @entity3167 and CA 19-9 as XXXX markers for @entity1358 .

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: Numerous @entity5 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity3167 ( @entity35419 ). CA 19-9 is a @entity1735 antigen found on the membrane surface of pancreatic, gastric, and @entity694 . A prospective study involving 25 @entity1 (15 males, 10 females) with @entity1358 ( @entity1358 ) was undertaken to examine the clinical value of these two markers. @entity1 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity1 . Twenty three of the 25 had known disease present when tested. Eleven @entity1 with no known @entity5 were used as an age-matched control group. Sixteen of the 23 @entity1 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity1 (82%) had normal LASA values. Three of 7 @entity1 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity1 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity5 stage. CA 19-9 values obtained in 15 of 25 @entity1 with @entity1358 were within normal range.

title: Significance of lipid-associated XXXX and CA 19-9 as @entity5 markers for @entity1358 .

answer: @entity3167 :: (MESH:D019158,Chemical) :: ['sialic acid']


abstract: A 2-year-old, female spayed Golden Retriever @entity235 was presented to The Ohio State University Veterinary Medical Center for evaluation of @entity2055 , @entity158 , 1 episode of @entity697 , dull mentation, and inappetence. Physical examination revealed an elevated temperature of 39.7  C and severe @entity158 . Blood work revealed a mature neutrophilia. Cerebrospinal fluid (CSF) analysis revealed nondegenerative neutrophilic pleocytosis with no infectious agents. A presumptive diagnosis of @entity479 -responsive @entity693 - @entity3468 was made, and @entity228 therapy was started. The @entity1 improved initially but experienced a vestibular episode characterized by falling and @entity346 . A magnetic resonance imaging of the brain revealed an @entity7181 in the cervical vertebral canal and diffuse meningeal enhancement in the brain and cranial cervical spine. Abscess drainage revealed degenerate neutrophils and several filamentous, branching organisms. Culture of the initial CSF using an enrichment broth revealed growth of a Gram-positive organism 5 days after fluid collection. The isolate was identified by partial 16S ribosomal DNA sequencing as Actinomyces spp. The @entity1 was successfully treated with long-term antibiotics. Our study reports the long-term survival after medical treatment of @entity2348 and epidural abscessation due to Actinomyces sp. infection in a @entity235 . @entity2348 should be included as a differential diagnosis in @entity1 with cervical @entity158 , even when a nondegenerative neutrophilic pleocytosis is found on CSF analysis. Culture of the CSF with use of an enrichment broth should be considered in all cases of neutrophilic pleocytosis to rule out infections of the central nervous system.

title: Long-term survival in a XXXX with meningoencephalitis and epidural abscessation due to Actinomyces species.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute collapse']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial meningoencephalitis', 'Bacterial meningoencephalitis']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity3468 :: ('MESH:D001167', 'Disease') :: ['arteritis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['cervical pain', 'pain and fever']

entities_list: @entity7181 :: ('MESH:D020802', 'Disease') :: ['epidural abscess']

entities_list: @entity346 :: ('MESH:D009759', 'Disease') :: ['vertical nystagmus']

answer: @entity235 :: (9615,Species) :: ['dog']


abstract: AIMS: We investigated the association between @entity6 duration and the extent and severity of @entity453 ( @entity453 ) as well as long-term clinical outcomes using coronary computed tomography angiography (CCTA) in asymptomatic type 2 @entity6 @entity1 . METHODS AND RESULTS: We analysed 933 asymptomatic type 2 @entity6 @entity1 without known @entity453 who underwent CCTA. @entity1 were divided into three groups according to the duration of @entity6 : <5 years, 5-10 years, and >= 10 years. Stenosis by CCTA was scored as none (0%), non-obstructive (1-49%), or obstructive (>= 50%) for each coronary artery segment. For these @entity1 , we compared the prevalence, extent, and severity of @entity453 , including coronary artery @entity460 score (CACS), @entity1856 burden obstructive score (ABOS), segment involvement score (SIS), and segment @entity850 score (SSS). Major adverse cardiac and cerebrovascular events (MACCE), including all-cause mortality, non-fatal @entity583 , and @entity64 , within a follow-up period were also compared. @entity1 with longer duration of @entity6 possessed higher rates of obstructive @entity453 (P < 0.001). @entity1 with longer duration of @entity6 also manifested greater degree of CACS, ABOS, SIS, and SSS (P < 0.001 for all) with associated higher rate of MACCE (P = 0.025). Presence of obstructive @entity453 as assessed by CCTA was an independent predictor of MACCE after adjusting for confounding risk factors (hazard ratio: 1.979, confidence interval: 1.178-3.327, P = 0.010). CONCLUSION: In asymptomatic @entity6 @entity1 , longer @entity6 duration is associated with a higher prevalence, extent, and severity of @entity453 as well as risk of MACCE. Moreover, greater @entity453 burden increases the risk of MACCE independent of co-existing @entity453 risk factors.

title: Impact of @entity6 duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 XXXX @entity1 : evaluation by Coronary CT angiography.

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: AIMS: We investigated the association between @entity6 duration and the extent and severity of @entity453 ( @entity453 ) as well as long-term clinical outcomes using coronary computed tomography angiography (CCTA) in asymptomatic type 2 @entity6 @entity1 . METHODS AND RESULTS: We analysed 933 asymptomatic type 2 @entity6 @entity1 without known @entity453 who underwent CCTA. @entity1 were divided into three groups according to the duration of @entity6 : <5 years, 5-10 years, and >= 10 years. Stenosis by CCTA was scored as none (0%), non-obstructive (1-49%), or obstructive (>= 50%) for each coronary artery segment. For these @entity1 , we compared the prevalence, extent, and severity of @entity453 , including coronary artery @entity460 score (CACS), @entity1856 burden obstructive score (ABOS), segment involvement score (SIS), and segment @entity850 score (SSS). Major adverse cardiac and cerebrovascular events (MACCE), including all-cause mortality, non-fatal @entity583 , and @entity64 , within a follow-up period were also compared. @entity1 with longer duration of @entity6 possessed higher rates of obstructive @entity453 (P < 0.001). @entity1 with longer duration of @entity6 also manifested greater degree of CACS, ABOS, SIS, and SSS (P < 0.001 for all) with associated higher rate of MACCE (P = 0.025). Presence of obstructive @entity453 as assessed by CCTA was an independent predictor of MACCE after adjusting for confounding risk factors (hazard ratio: 1.979, confidence interval: 1.178-3.327, P = 0.010). CONCLUSION: In asymptomatic @entity6 @entity1 , longer @entity6 duration is associated with a higher prevalence, extent, and severity of @entity453 as well as risk of MACCE. Moreover, greater @entity453 burden increases the risk of MACCE independent of co-existing @entity453 risk factors.

title: Impact of XXXX duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 @entity6 @entity1 : evaluation by Coronary CT angiography.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: AIMS: We investigated the association between @entity6 duration and the extent and severity of @entity453 ( @entity453 ) as well as long-term clinical outcomes using coronary computed tomography angiography (CCTA) in asymptomatic type 2 @entity6 @entity1 . METHODS AND RESULTS: We analysed 933 asymptomatic type 2 @entity6 @entity1 without known @entity453 who underwent CCTA. @entity1 were divided into three groups according to the duration of @entity6 : <5 years, 5-10 years, and >= 10 years. Stenosis by CCTA was scored as none (0%), non-obstructive (1-49%), or obstructive (>= 50%) for each coronary artery segment. For these @entity1 , we compared the prevalence, extent, and severity of @entity453 , including coronary artery @entity460 score (CACS), @entity1856 burden obstructive score (ABOS), segment involvement score (SIS), and segment @entity850 score (SSS). Major adverse cardiac and cerebrovascular events (MACCE), including all-cause mortality, non-fatal @entity583 , and @entity64 , within a follow-up period were also compared. @entity1 with longer duration of @entity6 possessed higher rates of obstructive @entity453 (P < 0.001). @entity1 with longer duration of @entity6 also manifested greater degree of CACS, ABOS, SIS, and SSS (P < 0.001 for all) with associated higher rate of MACCE (P = 0.025). Presence of obstructive @entity453 as assessed by CCTA was an independent predictor of MACCE after adjusting for confounding risk factors (hazard ratio: 1.979, confidence interval: 1.178-3.327, P = 0.010). CONCLUSION: In asymptomatic @entity6 @entity1 , longer @entity6 duration is associated with a higher prevalence, extent, and severity of @entity453 as well as risk of MACCE. Moreover, greater @entity453 burden increases the risk of MACCE independent of co-existing @entity453 risk factors.

title: Impact of @entity6 duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 @entity6 XXXX : evaluation by Coronary CT angiography.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: @entity170 is a significant cause of morbidity and mortality in the elderly and an important public health issue. @entity171 are the primary treatment options for @entity170 . The oral administration of @entity171 may result in poor @entity1 compliance and thence reduced treatment efficacy. Intravenously administered @entity171 may therefore show better treatment efficacy. We have carried out a meta-analysis to evaluate the efficacy of @entity4381 treatment for @entity170 in both @entity1 and @entity1 with either @entity174 . MATERIAL AND METHODS: Randomized controlled trials with @entity4381 treatment for @entity170 were retrieved from PubMed, EMBASE and clinicaltrials.gov. The risk ratio with 95% confidence interval (RR, 95% CI) was calculated to evaluate the effect of @entity4381 treatment on incidence of @entity174 . Data on changes in @entity79 ( @entity79 ) following @entity4381 ( @entity5921 ) treatment was also extracted. STATA software was used for all the statistical analyses. RESULTS: Significant reduction in the incidence of both vertebral and nonvertebral @entity174 was observed following @entity5921 treatment, as seen from the values for RR with 95% CI (RR 0.24 and 95% CI 0.15 to 0.40 for @entity174 ; RR 0.76 and 95% CI 0.67 to 0.86 for @entity174 ). @entity79 was also seen to be increased after @entity5921 treatment. CONCLUSION: Ourmeta-analysis showed that @entity4381 was effective in reducing the incidence of @entity174 as well as @entity174 , including @entity173 . Significant increase in @entity79 ( @entity79 ) was also observed in @entity1 administered @entity5921 as compared to placebo.

title: Efficacy of @entity4381 in treatment of XXXX in @entity1 and @entity1 -a meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates', 'Bisphosphonates']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['nonvertebral fractures', 'vertebral fractures', 'vertebral or non-vertebral fracture', 'fracture']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'osteoporosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['hip fractures']

entities_list: @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid']

answer: @entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']


abstract: BACKGROUND: @entity170 is a significant cause of morbidity and mortality in the elderly and an important public health issue. @entity171 are the primary treatment options for @entity170 . The oral administration of @entity171 may result in poor @entity1 compliance and thence reduced treatment efficacy. Intravenously administered @entity171 may therefore show better treatment efficacy. We have carried out a meta-analysis to evaluate the efficacy of @entity4381 treatment for @entity170 in both @entity1 and @entity1 with either @entity174 . MATERIAL AND METHODS: Randomized controlled trials with @entity4381 treatment for @entity170 were retrieved from PubMed, EMBASE and clinicaltrials.gov. The risk ratio with 95% confidence interval (RR, 95% CI) was calculated to evaluate the effect of @entity4381 treatment on incidence of @entity174 . Data on changes in @entity79 ( @entity79 ) following @entity4381 ( @entity5921 ) treatment was also extracted. STATA software was used for all the statistical analyses. RESULTS: Significant reduction in the incidence of both vertebral and nonvertebral @entity174 was observed following @entity5921 treatment, as seen from the values for RR with 95% CI (RR 0.24 and 95% CI 0.15 to 0.40 for @entity174 ; RR 0.76 and 95% CI 0.67 to 0.86 for @entity174 ). @entity79 was also seen to be increased after @entity5921 treatment. CONCLUSION: Ourmeta-analysis showed that @entity4381 was effective in reducing the incidence of @entity174 as well as @entity174 , including @entity173 . Significant increase in @entity79 ( @entity79 ) was also observed in @entity1 administered @entity5921 as compared to placebo.

title: Efficacy of XXXX in treatment of @entity170 in @entity1 and @entity1 -a meta-analysis.

answer: @entity4381 :: (MESH:C088658,Chemical) :: ['zoledronic acid']


abstract: BACKGROUND: @entity170 is a significant cause of morbidity and mortality in the elderly and an important public health issue. @entity171 are the primary treatment options for @entity170 . The oral administration of @entity171 may result in poor @entity1 compliance and thence reduced treatment efficacy. Intravenously administered @entity171 may therefore show better treatment efficacy. We have carried out a meta-analysis to evaluate the efficacy of @entity4381 treatment for @entity170 in both @entity1 and @entity1 with either @entity174 . MATERIAL AND METHODS: Randomized controlled trials with @entity4381 treatment for @entity170 were retrieved from PubMed, EMBASE and clinicaltrials.gov. The risk ratio with 95% confidence interval (RR, 95% CI) was calculated to evaluate the effect of @entity4381 treatment on incidence of @entity174 . Data on changes in @entity79 ( @entity79 ) following @entity4381 ( @entity5921 ) treatment was also extracted. STATA software was used for all the statistical analyses. RESULTS: Significant reduction in the incidence of both vertebral and nonvertebral @entity174 was observed following @entity5921 treatment, as seen from the values for RR with 95% CI (RR 0.24 and 95% CI 0.15 to 0.40 for @entity174 ; RR 0.76 and 95% CI 0.67 to 0.86 for @entity174 ). @entity79 was also seen to be increased after @entity5921 treatment. CONCLUSION: Ourmeta-analysis showed that @entity4381 was effective in reducing the incidence of @entity174 as well as @entity174 , including @entity173 . Significant increase in @entity79 ( @entity79 ) was also observed in @entity1 administered @entity5921 as compared to placebo.

title: Efficacy of @entity4381 in treatment of @entity170 in XXXX and @entity1 -a meta-analysis.

answer: @entity1 :: (9606,Species) :: ['men']


abstract: BACKGROUND: @entity170 is a significant cause of morbidity and mortality in the elderly and an important public health issue. @entity171 are the primary treatment options for @entity170 . The oral administration of @entity171 may result in poor @entity1 compliance and thence reduced treatment efficacy. Intravenously administered @entity171 may therefore show better treatment efficacy. We have carried out a meta-analysis to evaluate the efficacy of @entity4381 treatment for @entity170 in both @entity1 and @entity1 with either @entity174 . MATERIAL AND METHODS: Randomized controlled trials with @entity4381 treatment for @entity170 were retrieved from PubMed, EMBASE and clinicaltrials.gov. The risk ratio with 95% confidence interval (RR, 95% CI) was calculated to evaluate the effect of @entity4381 treatment on incidence of @entity174 . Data on changes in @entity79 ( @entity79 ) following @entity4381 ( @entity5921 ) treatment was also extracted. STATA software was used for all the statistical analyses. RESULTS: Significant reduction in the incidence of both vertebral and nonvertebral @entity174 was observed following @entity5921 treatment, as seen from the values for RR with 95% CI (RR 0.24 and 95% CI 0.15 to 0.40 for @entity174 ; RR 0.76 and 95% CI 0.67 to 0.86 for @entity174 ). @entity79 was also seen to be increased after @entity5921 treatment. CONCLUSION: Ourmeta-analysis showed that @entity4381 was effective in reducing the incidence of @entity174 as well as @entity174 , including @entity173 . Significant increase in @entity79 ( @entity79 ) was also observed in @entity1 administered @entity5921 as compared to placebo.

title: Efficacy of @entity4381 in treatment of @entity170 in @entity1 and XXXX -a meta-analysis.

answer: @entity1 :: (9606,Species) :: ['women']


abstract: OBJECTIVE: It is widely reported that @entity3804 (+)Gr1+ myeloid-derived suppressor cells can cause allograft tolerance in @entity19 and @entity1 , however, little is known on the therapy role in chronic transplantation rejection. In this paper, their role in corneal transplantation was studied for the first time. METHOD: Inhibitory @entity3804 (+) cells were obtained by @entity19 @entity558 -induced septic model. Phenotype, endocytosis, antigen presenting ability, and T cell suppression assays were performed by flow cytometry analysis. The suppressive ability in vivo was analyzed by targeting allogeneic corneal transplantation. RESULTS: @entity558 was intraperitoneally injected into C57BL/6 @entity19 , the percentage of @entity3804 (+) Gr1+ cells was increased in @entity19 spleen, blood, and bone marrow, respectively. Compared with control @entity19 , @entity19347 , @entity8932 , and MHC-11 expression were higher in @entity558 treated @entity19 . @entity3804 (+) Gr1+ cells could inhibit allogenic corneal reaction in vivo after adoptive transfer, in consistent with an observation of inhibition effect on the antigen presenting cells (APCs) and CD4+ T cells proliferation in vitro. CONCLUSION: @entity3804 (+) cells induced by @entity558 could function as inhibitory APCs, suppress CD4+ T cells proliferation and improve corneal allograft survival. Predictly, its application for cells transfer therapy in clinic in the further.

title: Protection by XXXX -induced inhibitory @entity3804 (+) cells on corneal allograft.

answer: @entity558 :: (MESH:C536528,Disease) :: ['LPS']


abstract: OBJECTIVE: It is widely reported that @entity3804 (+)Gr1+ myeloid-derived suppressor cells can cause allograft tolerance in @entity19 and @entity1 , however, little is known on the therapy role in chronic transplantation rejection. In this paper, their role in corneal transplantation was studied for the first time. METHOD: Inhibitory @entity3804 (+) cells were obtained by @entity19 @entity558 -induced septic model. Phenotype, endocytosis, antigen presenting ability, and T cell suppression assays were performed by flow cytometry analysis. The suppressive ability in vivo was analyzed by targeting allogeneic corneal transplantation. RESULTS: @entity558 was intraperitoneally injected into C57BL/6 @entity19 , the percentage of @entity3804 (+) Gr1+ cells was increased in @entity19 spleen, blood, and bone marrow, respectively. Compared with control @entity19 , @entity19347 , @entity8932 , and MHC-11 expression were higher in @entity558 treated @entity19 . @entity3804 (+) Gr1+ cells could inhibit allogenic corneal reaction in vivo after adoptive transfer, in consistent with an observation of inhibition effect on the antigen presenting cells (APCs) and CD4+ T cells proliferation in vitro. CONCLUSION: @entity3804 (+) cells induced by @entity558 could function as inhibitory APCs, suppress CD4+ T cells proliferation and improve corneal allograft survival. Predictly, its application for cells transfer therapy in clinic in the further.

title: Protection by @entity558 -induced inhibitory XXXX (+) cells on corneal allograft.

answer: @entity3804 :: (16409(Tax:10090),Gene) :: ['CD11b']


abstract: Approximately 10% of @entity151 ( @entity151 ) cases develop @entity4264 ( @entity4264 ). Many @entity151 @entity1 with @entity4264 have relatively limited disease, requiring curative rather than palliative treatment. Besides chemotherapy, radiotherapy is important for treating @entity151 with @entity4264 . We retrospectively evaluated the influence of radiotherapy dose on the prognosis of 57 @entity1 with @entity151 with @entity4264 treated with concurrent chemoradiotherapy. The mean biological equivalent radiation dose was 71.5 Gy. We administered @entity2879 / @entity900 as sequential and concurrent chemotherapy. All @entity1 received at least one cycle of concurrent chemotherapy. All @entity1 had partial or complete response; @entity4264 -associated symptoms were reduced in 87.7% (50/57) of @entity1 within 3-10 days after treatment. Radiation dose did not affect 2-year local control (74.2% vs. 80.8%). @entity1 who received high-dose radiation had a lower 2-year overall survival rate than those who received low-dose radiation (11.6 vs. 33%; P = 0.024). The high dose group median survival was 15.0 months (95% confidence interval [CI]: 11.2-19.0) compared with 18.7 months (95% CI: 13.9-23.6) in the low dose group. Grade 3/4 @entity1398 occurred in 22/26 high dose @entity1 (84.6%) and 21/31 low dose @entity1 (67.7%). In the high dose group, 30.8% of @entity1 had grade 3/4 @entity2910 compared with 19.4% of low dose @entity1 . Only 29.0% of low dose @entity1 received < 4 cycles of chemotherapy in the first 12 weeks after treatment began compared with 46.2% of high dose @entity1 . Concurrent chemoradiotherapy is a tolerable modality for treating stage IIIA/IIIB @entity151 with @entity4264 . Moderate-dose radiotherapy is preferable.

title: Radiation dose is associated with prognosis of XXXX with @entity4264 .

entities_list: @entity4264 :: ('MESH:D013479', 'Disease') :: ['superior vena cava syndrome', 'SVCS']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small cell lung cancer']

answer: @entity151 :: (MESH:D055752,Disease) :: ['small cell lung cancer']


abstract: Approximately 10% of @entity151 ( @entity151 ) cases develop @entity4264 ( @entity4264 ). Many @entity151 @entity1 with @entity4264 have relatively limited disease, requiring curative rather than palliative treatment. Besides chemotherapy, radiotherapy is important for treating @entity151 with @entity4264 . We retrospectively evaluated the influence of radiotherapy dose on the prognosis of 57 @entity1 with @entity151 with @entity4264 treated with concurrent chemoradiotherapy. The mean biological equivalent radiation dose was 71.5 Gy. We administered @entity2879 / @entity900 as sequential and concurrent chemotherapy. All @entity1 received at least one cycle of concurrent chemotherapy. All @entity1 had partial or complete response; @entity4264 -associated symptoms were reduced in 87.7% (50/57) of @entity1 within 3-10 days after treatment. Radiation dose did not affect 2-year local control (74.2% vs. 80.8%). @entity1 who received high-dose radiation had a lower 2-year overall survival rate than those who received low-dose radiation (11.6 vs. 33%; P = 0.024). The high dose group median survival was 15.0 months (95% confidence interval [CI]: 11.2-19.0) compared with 18.7 months (95% CI: 13.9-23.6) in the low dose group. Grade 3/4 @entity1398 occurred in 22/26 high dose @entity1 (84.6%) and 21/31 low dose @entity1 (67.7%). In the high dose group, 30.8% of @entity1 had grade 3/4 @entity2910 compared with 19.4% of low dose @entity1 . Only 29.0% of low dose @entity1 received < 4 cycles of chemotherapy in the first 12 weeks after treatment began compared with 46.2% of high dose @entity1 . Concurrent chemoradiotherapy is a tolerable modality for treating stage IIIA/IIIB @entity151 with @entity4264 . Moderate-dose radiotherapy is preferable.

title: Radiation dose is associated with prognosis of @entity151 with XXXX .

answer: @entity4264 :: (MESH:D013479,Disease) :: ['superior vena cava syndrome']


abstract: OBJECTIVE: To investigate the clinical efficacy of gastric bypass surgery in @entity28 @entity1 with @entity164 2 @entity6 . METHODS: Clinical data of 58 @entity28 @entity1 with @entity164 2 @entity6 (body mass index range from 22.1-25.8 kg/m(2)) were collected one year after gastric bypass surgery. Collected parameters included fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin, fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1. The insulin resistance index (HOMA-IR = fasting plasma @entity413 * fasting serum insulin/22.5) and the body mass index were calculated. RESULTS: Of the 58 @entity1 , 48 had stopped taking all hypoglycemic drug treatments and had achieved complete remission (82.8%). Seven @entity1 were unable to completely withdraw from hypoglycemic agents, although their intake of drugs was reduced at least 50% compared to pre-surgical values (12.0%). Three of the cases showed no significant change in blood @entity413 after surgery (5.2%). In addition, values for fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin and HOMA-IR significantly decreased after surgery. Values for fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1 significantly increased after surgery, and the body mass index at the sixth post-operative month were significantly lower than pre-operative. CONCLUSION: For @entity28 @entity1 with @entity164 2 @entity6 , gastric bypass surgery has a significant clinical effect. Potential mechanisms include improvements in insulin resistance and/or increased endogenous intestinal glucagon-like peptide-1 secretion leading to improved insulin secretion.

title: Gastric bypass surgery in XXXX @entity1 with @entity6 : a 1-year follow-up of 58 cases in Chinese.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['non-obese']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity28 :: (MESH:D009765,Disease) :: ['non-obese']


abstract: OBJECTIVE: To investigate the clinical efficacy of gastric bypass surgery in @entity28 @entity1 with @entity164 2 @entity6 . METHODS: Clinical data of 58 @entity28 @entity1 with @entity164 2 @entity6 (body mass index range from 22.1-25.8 kg/m(2)) were collected one year after gastric bypass surgery. Collected parameters included fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin, fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1. The insulin resistance index (HOMA-IR = fasting plasma @entity413 * fasting serum insulin/22.5) and the body mass index were calculated. RESULTS: Of the 58 @entity1 , 48 had stopped taking all hypoglycemic drug treatments and had achieved complete remission (82.8%). Seven @entity1 were unable to completely withdraw from hypoglycemic agents, although their intake of drugs was reduced at least 50% compared to pre-surgical values (12.0%). Three of the cases showed no significant change in blood @entity413 after surgery (5.2%). In addition, values for fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin and HOMA-IR significantly decreased after surgery. Values for fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1 significantly increased after surgery, and the body mass index at the sixth post-operative month were significantly lower than pre-operative. CONCLUSION: For @entity28 @entity1 with @entity164 2 @entity6 , gastric bypass surgery has a significant clinical effect. Potential mechanisms include improvements in insulin resistance and/or increased endogenous intestinal glucagon-like peptide-1 secretion leading to improved insulin secretion.

title: Gastric bypass surgery in @entity28 @entity1 with XXXX : a 1-year follow-up of 58 cases in Chinese.

answer: @entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']


abstract: OBJECTIVE: To investigate the clinical efficacy of gastric bypass surgery in @entity28 @entity1 with @entity164 2 @entity6 . METHODS: Clinical data of 58 @entity28 @entity1 with @entity164 2 @entity6 (body mass index range from 22.1-25.8 kg/m(2)) were collected one year after gastric bypass surgery. Collected parameters included fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin, fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1. The insulin resistance index (HOMA-IR = fasting plasma @entity413 * fasting serum insulin/22.5) and the body mass index were calculated. RESULTS: Of the 58 @entity1 , 48 had stopped taking all hypoglycemic drug treatments and had achieved complete remission (82.8%). Seven @entity1 were unable to completely withdraw from hypoglycemic agents, although their intake of drugs was reduced at least 50% compared to pre-surgical values (12.0%). Three of the cases showed no significant change in blood @entity413 after surgery (5.2%). In addition, values for fasting plasma @entity413 , 2-hour postprandial blood @entity413 , glycosylated hemoglobin and HOMA-IR significantly decreased after surgery. Values for fasting plasma glucagon-like peptide-1 and 2-hour postprandial plasma glucagon-like peptide-1 significantly increased after surgery, and the body mass index at the sixth post-operative month were significantly lower than pre-operative. CONCLUSION: For @entity28 @entity1 with @entity164 2 @entity6 , gastric bypass surgery has a significant clinical effect. Potential mechanisms include improvements in insulin resistance and/or increased endogenous intestinal glucagon-like peptide-1 secretion leading to improved insulin secretion.

title: Gastric bypass surgery in @entity28 XXXX with @entity6 : a 1-year follow-up of 58 cases in Chinese.

answer: @entity1 :: (9606,Species) :: ['patients']